advertisement
Editors Selection IGR 24-4
Prognostic factors: Oxygen consumption rates in peripheral mononuclears could be a biomarker for progressive glaucoma
Comment by Jost Jonas on:
120564 Peripheral blood mononuclear cell respiratory function is associated with progressive glaucomatous vision loss, Petriti B; Rabiolo A; Chau KY et al., Nature Medicine, 2024; 30: 2362-2370
While several risk factors have been identified for the development and progression of glaucoma, the therapeutic reduction in intraocular pressure (IOP) has remained the only evidence-proven method to reduce risk of development and progression of glaucoma.1 In a new study, Petriti, Garway-Heath and colleagues reported that a lower oxygen consumption rate in mononuclear cell of the peripheral blood was strongly associated with faster perimetric glaucoma progression in patients under IOP-lowering therapy.2 It explained 13% of the variance in the rate of glaucoma progression. In another group of untreated patients with glaucoma, IOP explained 16% of the variance in perimetric glaucoma progression. Interestingly, the oxygen consumption rate was lower in patients with glaucoma than in controls, and it was lower in patients with glaucoma and low baseline IOP than those with high baseline IOP. In a parallel manner, the nicotinamide adenine dinucleotide levels in peripheral blood mononuclear cells were lower in patients with glaucoma than in controls and it was strongly correlated with the oxygen consumption rate.
If the results of this pilot study are confirmed, the oxygen consumption of peripheral mononuclear blood cells and the nicotinamide adenine dinucleotide level may become new biomarkers for progressive glaucoma
If the results of this pilot study are confirmed, the oxygen consumption of peripheral mononuclear blood cells and the nicotinamide adenine dinucleotide level may become new biomarkers for progressive glaucoma. The results of this study may also be of interest for ongoing studies on the use of nicotinamide for the therapy of patients with normal-pressure glaucoma.3
References
- Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara- Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, place-bo-controlled trial. Lancet. 2015;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5.
- Petriti B, Rabiolo A, Chau KY, Williams PA, Montesano G, Lascaratos G, Garway-Heath DF. Peripheral blood mononuclear cell respiratory function is associated with progressive glaucomatous vision loss. Nat Med. 2024;30(8):2362-2370. doi: 10.1038/ s41591-024-03068-6.
- De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. Nicotinamide and pyruvate for neuroen-hancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmol. 2022;140(1):11-18.
Comments
The comment section on the IGR website is restricted to WGA#One members only. Please log-in through your WGA#One account to continue.Log-in through WGA#One
